TY - JOUR
T1 - Blood biomarkers in paediatric mild traumatic brain injury
T2 - a systematic review
AU - Lugones, Micaela
AU - Parkin, Georgia
AU - Bjelosevic, Stefan
AU - Takagi, Michael
AU - Clarke, Cathriona
AU - Anderson, Vicki
AU - Ignjatovic, Vera
N1 - Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/4
Y1 - 2018/4
N2 - Objective: To summarize all current studies focusing on blood biomarkers in paediatric mild traumatic brain injury (mTBI) and to outline the possible use of blood biomarkers for diagnostic, prognostic and monitoring purposes within this setting. Methods: A systematic review following the PRISMA guidelines was conducted using the MEDLINE, PubMed and EMBASE databases. Results: A total of 21 studies were included in the review, encompassing a total of 14 different biomarkers. Seventeen (81%) of these studies found a significant association between biomarker concentration and mTBI characteristics, however results from studies to date are diverse and at times conflicting. Conclusion: GFAP appears to be a promising blood biomarker for the prognosis and monitoring of mTBI, whereas UCH-L1 appears more promising at mTBI diagnosis. Despite this, the overall heterogeneity in assessed biomarkers, study design and measurement tools has made drawing specific conclusions challenging. Future research will require more uniform study design and methodological approaches to allow for the comparison, corroboration and validation of blood biomarkers within the context of paediatric mTBI.
AB - Objective: To summarize all current studies focusing on blood biomarkers in paediatric mild traumatic brain injury (mTBI) and to outline the possible use of blood biomarkers for diagnostic, prognostic and monitoring purposes within this setting. Methods: A systematic review following the PRISMA guidelines was conducted using the MEDLINE, PubMed and EMBASE databases. Results: A total of 21 studies were included in the review, encompassing a total of 14 different biomarkers. Seventeen (81%) of these studies found a significant association between biomarker concentration and mTBI characteristics, however results from studies to date are diverse and at times conflicting. Conclusion: GFAP appears to be a promising blood biomarker for the prognosis and monitoring of mTBI, whereas UCH-L1 appears more promising at mTBI diagnosis. Despite this, the overall heterogeneity in assessed biomarkers, study design and measurement tools has made drawing specific conclusions challenging. Future research will require more uniform study design and methodological approaches to allow for the comparison, corroboration and validation of blood biomarkers within the context of paediatric mTBI.
UR - http://www.scopus.com/inward/record.url?scp=85042207681&partnerID=8YFLogxK
U2 - 10.1016/j.neubiorev.2018.02.006
DO - 10.1016/j.neubiorev.2018.02.006
M3 - Review Article
C2 - 29462640
AN - SCOPUS:85042207681
SN - 0149-7634
VL - 87
SP - 206
EP - 217
JO - Neuroscience and Biobehavioral Reviews
JF - Neuroscience and Biobehavioral Reviews
ER -